Cisplatin-gemcitabine as palliative chemotherapy in advanced squamous vulvar carcinoma: report of two cases

Vulvar cancer (VC) is a rare disease, usually diagnosed in a stage still amenable to potentially curative treatments, including surgery and/or radiation therapy with or without chemotherapy. Several patients however present at diagnosis with metastatic disease and another 30-50% will relapse. Prognosis of metastatic or recurrent disease not amenable to salvage surgery or radiotherapy is very poor. Evidence about the efficacy of chemotherapy in this setting is limited and its role still remains unclear. At present there is no standard treatment for advanced VC and patients are usually treated with schedules adopted for chemoradiation or extrapolated from cervical cancer. We report our experience using a cisplatin-gemcitabine regimen in two cases of metastatic squamous cell VC. No response was obtained with this schedule. No other data are available in the literature about the choice of a cisplatin-gemcitabine regimen in this patient subset. The paucity of evidence about the role of palliative chemotherapy in metastatic VC justifies any effort to implement knowledge. For this reason we think it is notable to also report a negative experience. It is not possible for us to conclude that this chemotherapy would be unable to provide any benefit in a larger sample of patients; nonetheless we think that new agents, rather than combinations of older drugs, could hopefully provide more benefit.

Vulvar cancer; Chemotherapy; Gemcitabine

[1] Jemal A., Center M.M., Ward E., Thun M.J.: “Cancer occurrence”. Methods Mol. Biol., 2009, 471, 3.

[2] Olawaiye A., Lee L.M., Krasner C., Horowitz N.: “Treatment of squamous cell vulvar cancer with the anti-EGFR tyrosine kinase inhibitor Tarceva”. Gynecol. Oncol., 2007, 106, 628.

[3] Fonseca-Moutinho J.A.: “Recurrent vulvar cancer”. Clin. Obstet. Gynecol., 2005, 48, 879.

[4] Cormio G., Loizzi V., Gissi F., Serrati G., Panzarino M., Carriero C., Selvaggi L.: “Cisplatin and vinorelbine chemotherapy in recurrent vulvar carcinoma”. Oncology, 2009, 77, 281.

[5] Durrant K.R., Mangioni C., Lacave A.J., George M., van der Burg M.E., Guthrie D. et al.: “Bleomycin, methotrexate, and CCNU in advanced inoperable squamous cell carcinoma of the vulva: a phase II study of the EORTC Gynaecological Cancer Cooperative Group (GCCG)”. Gynecol. Oncol., 1990, 37, 359.

[6] Benedetti-Panici P., Greggi S., Scambia G., Salerno G., Mancuso S.: “Cisplatin (P), bleomycin (B), and methotrexate (M) preoperative chemotherapy in locally advanced vulvar carcinoma”. Gynecol. Oncol., 1993, 50, 49.

[7] Geisler J.P., Manahan K.J., Buller R.E.: “Neoadjuvant chemotherapy in vulvar cancer: avoiding primary exenteration”. Gynecol. Oncol., 2006, 100, 53.

[8] Wagenaar H.C., Colombo N., Vergote I., Hoctin-Boes G., Zanetta G., Pecorelli S. et al.: “Bleomycin, methotrexate, and CCNU in locally advanced or recurrent, inoperable, squamous-cell carcinoma of the vulva: an EORTC Gynaecological Cancer Cooperative Group Study. European Organization for Research and Treatment of Cancer”. Gynecol. Oncol., 2001, 81, 348.

[9] Domingues A.P., Mota F., Durão M., Frutuoso C., Amaral N., de Oliveira C.F.: “Neoadjuvant chemotherapy in advanced vulvar cancer”. Int. J. Gynecol. Cancer; 2010, 20, 294.

[10] Witteveen P.O., van der Velden J., Vergote I., Guerra C., Scarabeli C., Coens C. et al.: “Phase II study on paclitaxel in patients with recurrent, metastatic or locally advanced vulvar cancer not amenable to surgery or radiotherapy: a study of the EORTC-GCG (European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group)”. Ann. Oncol., 2009, 20, 1511.

[11] Bacha O.M., Levesque E., Renaud M.C., Lalancette M.: “A case of recurrent vulvar carcinoma treated with erlotinib, an EGFR inhibitor”. Eur. J. Gynaecol. Oncol., 2011, 32, 423.

[12] Monk B.J., Sill M.W., McMeekin D.S., Cohn D.E., Ramondetta L.M., Boardman C.H. et al.: “Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study”. J. Clin. Oncol. 2009, 27, 4649.

[13] Brewer C.A., Blessing J.A., Nagourney R.A., McMeekin D.S., Lele S., Zweizig S.: “Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group”. Gynecol. Onco1., 2006, 100, 385.

[14] Richard S.D., Krivak T.C., Beriwal S., Zorn K.K.: “Recurrent metastatic vulvar carcinoma treated with cisplatin plus cetuximab”. Int. J. Gynecol. Cancer, 2008, 18, 1132.